List of Excipients in Branded Drug HALOPERIDOL LACTATE

« Back to Dashboard

Generic Drugs Containing HALOPERIDOL LACTATE

Company	Ingredient	NDC	Excipient
Henry Schein Inc	haloperidol	0404-9871	LACTIC ACID
Henry Schein Inc	haloperidol	0404-9871	METHYLPARABEN
Henry Schein Inc	haloperidol	0404-9871	PROPYLPARABEN

What are the Most Frequently-Used Excipients in HALOPERIDOL LACTATE?

# Of NDCs	Excipient
5	LACTIC ACID
5	METHYLPARABEN
5	PROPYLPARABEN

Haloperidol Lactate Excipient Strategy and Commercial Opportunities

Last updated: September 14, 2026

Haloperidol lactate is an established, low-cost injectable antipsychotic with limited active-ingredient patent protection and high substitution pressure. The commercial opportunity is concentrated in formulation execution: preservative-free presentation, ready-to-administer packaging, pH and osmolality control, compatibility, supply reliability, and differentiated hospital distribution. The core product is an acidic aqueous solution, typically 5 mg/mL, using water for injection and lactic acid, with sodium hydroxide or another pH adjuster where required. The greatest technical risk is not active-ingredient novelty but maintaining chemical stability, physical clarity, container compatibility, and injection tolerability.

What is haloperidol lactate and how is it supplied?

Haloperidol lactate is the water-soluble lactate salt of haloperidol used primarily for intramuscular administration and, in some labeling, intravenous use under controlled clinical conditions. It is distinct from haloperidol decanoate, the long-acting depot ester.

Attribute	Haloperidol lactate
Active ingredient	Haloperidol lactate
Therapeutic class	Butyrophenone antipsychotic
Typical injectable strength	5 mg/mL
Common route	Intramuscular; intravenous use depends on product labeling and institutional practice
Dosage form	Sterile aqueous injection
Depot formulation	No; haloperidol decanoate is the depot product
Typical excipients	Water for injection, lactic acid, pH adjuster
Preservative status	Product-specific; many presentations are preservative-free
Regulatory pathway	Abbreviated New Drug Application for generics; NDA for branded reference products
Biosimilar relevance	None; haloperidol lactate is a small-molecule drug

U.S. labeling for Haldol injection identifies haloperidol lactate as the active ingredient and lists lactic acid and water for injection among the formulation components. The product is an acidic solution, with pH controlled within a range suitable for chemical stability and injectable use (Janssen Pharmaceuticals, 2019; DailyMed, 2024a).

What excipients are used in haloperidol lactate injection?

The standard excipient strategy is deliberately narrow. A typical formulation contains:

1. Water for injection as the vehicle.
2. Lactic acid as the counterion and formulation acid.
3. Sodium hydroxide or another alkaline agent for pH adjustment, when needed.

The formulation does not generally require a cosolvent, surfactant, suspending agent, antioxidant, or complex buffering system. This reduces excipient-related regulatory and manufacturing risk but leaves fewer opportunities to differentiate the product through composition alone.

Why is lactic acid used?

Lactic acid forms the lactate salt and supports an acidic formulation environment. The salt improves aqueous handling compared with the poorly water-soluble free base. The formulation must balance several requirements:

• Adequate drug solubility.
• Control of precipitation during storage.
• Acceptable injection characteristics.
• Chemical stability.
• Compatibility with the container closure system.
• Reproducible pH after sterilization and over shelf life.

Excessive acidification can increase injection discomfort and accelerate container or stopper interactions. Insufficient acidity can create precipitation risk or reduce assay stability.

Is a preservative necessary?

A preservative is not necessary for a single-dose, preservative-free presentation. Multidose packaging may create a commercial rationale for antimicrobial preservation, but the regulatory and clinical tradeoff is unfavorable in many hospital settings. Preservatives can create toxicity, hypersensitivity, compatibility, and labeling issues.

The preferred strategy for emergency and acute-care use is usually a single-dose ampule or vial with a low extractables profile and no antimicrobial preservative. The FDA Inactive Ingredient Database can be used to assess precedent for excipients, routes, and dosage forms, but it does not replace product-specific formulation and safety studies (U.S. Food and Drug Administration, 2024a).

What formulation patents protect haloperidol lactate?

Haloperidol lactate has limited composition-of-matter value because haloperidol was developed decades ago. The main commercial product is therefore exposed to generic competition. Potential intellectual-property coverage is more likely to concern:

• Specific injectable concentrations.
• Container-closure systems.
• Premixed or ready-to-administer presentations.
• Stability improvements.
• Alternative salts or pH systems.
• Infusion-compatible formulations.
• Packaging configurations.
• Manufacturing and sterilization processes.
• Narrow method-of-use claims.

A new product cannot assume that a different ampule, vial size, or pH target creates meaningful patent strength. Patentability would depend on unexpected stability, improved tolerability, reduced adsorption, superior compatibility, or another measurable technical effect.

How strong is the patent estate for haloperidol lactate?

The patent estate is weak for the active ingredient and conventional injectable formulation. A new entrant would face greater commercial risk from price competition and hospital contracting than from blocking patents. Any diligence should review:

• FDA Orange Book listings.
• Google Patents and national patent registers.
• ANDA Paragraph IV certifications.
• Patent-term adjustments and terminal disclaimers.
• State and federal litigation records.
• Product-specific exclusivity and discontinued-drug determinations.

The Orange Book generally lists patents and exclusivity for approved innovator products, but generic injectable products may have little remaining patent protection where the underlying patents have expired or are no longer relevant (U.S. Food and Drug Administration, 2024b).

When does haloperidol lactate lose exclusivity?

Haloperidol lactate has already lost its primary small-molecule exclusivity in the United States. The relevant commercial condition is generic competition, not an impending loss of innovative exclusivity.

Exclusivity category	Haloperidol lactate status
New chemical entity exclusivity	Expired
Pediatric exclusivity	No current strategic relevance
Orphan exclusivity	Not applicable to the conventional product
Reference-product patent barrier	Generally limited or expired
Generic entry	Established
Biosimilar exclusivity	Not applicable

The commercial product should therefore be evaluated as a mature injectable generic. Market entry economics depend on supply continuity, approved presentations, hospital formulary access, and procurement pricing.

What FDA regulatory status applies to haloperidol lactate?

A generic haloperidol lactate injection generally proceeds through an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence or meet the applicable waiver or comparative requirements for the dosage form. Injectable products also require controls for:

• Sterility.
• Bacterial endotoxins.
• Particulate matter.
• Visible foreign matter.
• Container-closure integrity.
• Assay and impurities.
• Extractable volume.
• pH and osmolality.
• Subvisible particles.
• Stability after sterilization.

For a sterile solution, formulation simplicity does not eliminate development risk. A small change in pH adjuster, stopper elastomer, glass type, or sterilization cycle can affect impurities, appearance, or shelf life.

What excipient strategy creates the strongest commercial opportunity?

1. Preservative-free single-dose presentation

A preservative-free ampule or vial is the lowest-risk differentiation route. It aligns with acute-care use and can reduce concerns about repeated exposure to antimicrobial preservatives. The commercial value depends on supply reliability and procurement contracts rather than patent exclusivity.

2. Ready-to-administer packaging

A prefilled syringe or unit-dose ready-to-administer format could reduce medication-preparation steps, occupational exposure, and dosing errors. The development burden is higher because the sponsor must qualify:

• Syringe materials.
• Lubricants.
• Needle and plunger compatibility.
• Drug adsorption.
• Silicone-related particles.
• Container-closure integrity.
• Autoinjector or safety-device performance.

The strongest business case is in emergency departments, psychiatric facilities, correctional healthcare, and ambulance systems where speed and standardized administration have operational value.

3. Low-volume high-concentration product

The conventional 5 mg/mL strength already supports low injection volume. A higher concentration could reduce volume further but would require evidence that the product remains soluble, chemically stable, and tolerable. A high-concentration product may also create dosing-error risk if it is not clearly differentiated from existing presentations.

4. Improved pH and injection tolerability

A formulation with reduced acidity could have commercial value if it preserves solubility and stability while improving local tolerability. This is technically difficult because haloperidol lactate relies on an acidic environment. A buffered system may introduce new risks, including precipitation during dilution, ionic-strength changes, and compatibility problems.

5. Extended in-use stability

Hospitals may value a product that remains stable after withdrawal into a syringe or after dilution under specified conditions. The opportunity depends on validated in-use data, microbial controls, container compatibility, and clear labeling. Extended in-use claims should not be based only on chemical assay; visible and subvisible particles, pH drift, and sterility controls are also relevant.

6. Hospital-system packaging

Unit-dose cartons, barcode-ready labels, tamper evidence, and automated-dispensing-compatible packaging may generate more practical value than a new excipient. Packaging should support medication-use systems, including GS1 barcodes, clear concentration displays, and differentiation from haloperidol decanoate.

What manufacturing and intellectual-property barriers exist?

The principal manufacturing barriers are process and quality-control barriers:

• Sterile compounding and aseptic processing.
• Terminal sterilization feasibility.
• Control of haloperidol-related impurities.
• Reproducible pH adjustment.
• Prevention of precipitation.
• Glass and elastomer compatibility.
• Low particulate burden.
• Container-closure integrity.
• Reliable commercial-scale filling.

A terminally sterilized product may offer lower microbiological risk than an aseptically filled product, but the sponsor must show that the heat cycle does not increase degradation or alter container performance. If terminal sterilization is unsuitable, aseptic processing increases facility, validation, and supply-chain requirements.

The most defensible patent position would cover a demonstrated technical improvement, such as a specific pH and excipient range that produces unexpected stability, a container system that suppresses adsorption or particle formation, or a ready-to-administer device with validated performance.

Which companies are challenging or competing with haloperidol lactate?

Competition is primarily from generic injectable manufacturers and from alternative haloperidol products rather than from biosimilar developers. Relevant competitor groups include:

• Generic injectable manufacturers with approved haloperidol lactate injections.
• Branded or authorized-generic suppliers.
• Manufacturers of haloperidol decanoate.
• Alternative acute agitation products, including injectable antipsychotics with different safety and administration profiles.
• Institutional compounders, where legally permitted and commercially relevant.

The direct competitive set should be assessed by National Drug Code, approved strength, package size, shortage history, wholesaler availability, and hospital contract status. Manufacturer count alone is not a reliable measure of competitive intensity because sterile injectables can experience sudden supply concentration when one or more suppliers leave the market.

What patent litigation and Paragraph IV risks exist?

For a mature generic injectable, Paragraph IV risk is generally lower than for a recently launched product with active formulation or method-of-use patents. A Paragraph IV filing could still arise if a company seeks to launch:

• A novel ready-to-administer presentation.
• A new concentration.
• A new stability profile.
• A device-linked product.
• A formulation designed around an unexpired patent.

A Paragraph IV certification may trigger litigation under the Hatch-Waxman framework. The relevant commercial question is whether the challenged patent can support a preliminary injunction or settlement delay. For conventional haloperidol lactate injection, the larger risk is often regulatory approval timing, manufacturing readiness, and price erosion rather than patent litigation.

Settlement agreements should be reviewed for launch dates, authorized-generic provisions, supply commitments, acceleration clauses, and treatment of later-developed formulations. No biosimilar litigation pathway applies because haloperidol lactate is a small molecule.

How does haloperidol lactate compare with haloperidol decanoate?

Factor	Haloperidol lactate	Haloperidol decanoate
Role	Acute or short-term injectable treatment	Long-acting maintenance treatment
Chemistry	Lactate salt	Decanoate ester
Vehicle	Typically aqueous	Oil-based depot formulation
Administration	More frequent dosing	Extended dosing interval
Excipient issues	pH, precipitation, injection tolerability	Oil vehicle, depot release, viscosity, syringeability
Commercial differentiation	Packaging, readiness, stability, supply	Release profile, device, dosing interval, adherence
Biosimilar risk	None	None
Generic pressure	High	High but product-specific

The two products should not be treated as interchangeable formulation opportunities. A lactate product competes in acute-care workflow. A decanoate product competes in long-acting treatment and adherence management.

What revenue exposure and launch scenarios exist?

Revenue exposure is highest where the product is used routinely across emergency, inpatient psychiatric, correctional, and institutional settings. The product is inexpensive on a per-dose basis, so the business case depends on volume, contract retention, and operational differentiation.

Base-case generic launch

A conventional 5 mg/mL vial or ampule would require low development investment but face rapid price competition. This strategy is suitable for a manufacturer with existing sterile injectable capacity and a hospital sales channel.

Premium ready-to-administer launch

A prefilled syringe could command a higher net price if it reduces preparation time and medication errors. The product would face higher device, human-factors, and stability costs. Hospital adoption would depend on pharmacy-and-therapeutics review and purchasing evidence.

Supply-security launch

A manufacturer could compete through dual-site manufacturing, larger safety stock, and reliable shortage performance. This is a commercial strategy rather than a patent strategy. It may be attractive to group purchasing organizations and public-sector buyers.

Formulation-improvement launch

A pH-optimized or extended-stability product offers the strongest potential for intellectual-property protection but also the highest technical risk. Any premium claim must be supported by comparative data showing a clinically or operationally relevant improvement.

What geographic coverage is available?

U.S. approval does not establish global market access. Excipients, packaging, sterility standards, and labeling must be assessed by jurisdiction.

Region	Primary regulatory considerations
United States	ANDA, USP sterility and particulate requirements, Orange Book reference-product framework
European Union	Marketing authorization, European Pharmacopoeia compliance, centralized or national procedure depending on product strategy
United Kingdom	MHRA application and post-Brexit national requirements
Canada	Abbreviated new drug submission and Health Canada quality requirements
Japan	PMDA review, Japanese Pharmacopoeia and local labeling requirements
Emerging markets	Local registration, import controls, pharmacopoeial standards, public procurement

A global formulation should avoid unnecessary excipients that lack regulatory precedent in target markets. A simple water-lactic-acid system generally has a favorable regulatory profile, although each manufacturer must establish its own quality and stability data.

Key Takeaways

• Haloperidol lactate is a mature generic injectable with little active-ingredient exclusivity remaining.
• The conventional formulation is a simple acidic aqueous solution using water for injection, lactic acid, and pH adjustment.
• The strongest commercial opportunities are preservative-free single-dose packaging, ready-to-administer syringes, hospital-focused labeling, and supply reliability.
• Novel excipient patents are difficult to sustain unless they produce measurable and unexpected improvements in stability, tolerability, compatibility, or administration.
• The main barriers are sterile manufacturing, impurity control, pH management, container compatibility, and particulate control.
• Biosimilar risk is irrelevant because haloperidol lactate is a small-molecule drug.
• Haloperidol lactate and haloperidol decanoate address different markets and require different formulation strategies.
• Generic launch economics are driven more by procurement access and manufacturing reliability than by patent exclusivity.

FAQs

Is haloperidol lactate the same as haloperidol decanoate?

No. Haloperidol lactate is generally an aqueous injectable salt used for acute treatment. Haloperidol decanoate is an oil-based long-acting depot ester.

Can a new excipient create market exclusivity for haloperidol lactate?

Potentially, but only if the formulation produces a patentable and non-obvious technical benefit. Routine pH adjustment or substitution of common pharmaceutical excipients is unlikely to provide strong protection by itself.

Is haloperidol lactate injection usually preservative-free?

Many single-dose injectable presentations are preservative-free, but status is product-specific. The approved label and package insert control.

What is the most attractive differentiated presentation?

A ready-to-administer, preservative-free prefilled syringe is the clearest premium opportunity, subject to device compatibility, stability, particulate, and human-factors validation.

Does haloperidol lactate face biosimilar competition?

No. Biosimilar pathways apply to biological products. Haloperidol lactate competes through conventional generic-drug pathways.

References

DailyMed. (2024a). Haloperidol lactate injection, solution: Prescribing information. U.S. National Library of Medicine.

Janssen Pharmaceuticals, Inc. (2019). Haldol injection: Full prescribing information. U.S. Food and Drug Administration.

U.S. Food and Drug Administration. (2024a). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.